Has Thomas Donner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $359 in general payments to Thomas Donner, MD across 3 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Thomas Donner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Thomas Donner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Thomas Donner, MD

Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1659329977

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.7% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Digital Diagnostics Inc. accounts for 87.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MD, where the typical reported total is $1,404.

$359in general payments, 2019–2025

Across 3 payments — averaging $119.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Digital Diagnostics Inc.$315
Abbott$44

$196,244in research payments, 2019–2025

Across 3 payments — averaging $65,415 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Vertex$196K

What the payments were for

Food & beverage$32992%
Other$308%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Digital Diagnostics Inc.	1	$315
Abbott	2	$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IDx-DR$315

How this compares

$359 in reported general payments places this provider in the 25th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland →

Medicare billing

Part B allowed, 2024

$47,818

Medicare patients

276

Services billed

520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	323	$441,778
OzempicSemaglutide	178	$274,908
JardianceEmpagliflozin	174	$239,643
TrulicityDulaglutide	60	$95,403
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	45	$79,978
JanuviaSitagliptin Phosphate	38	$60,134
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	63	$37,978
TradjentaLinagliptin	41	$37,152
Tresiba Flextouch U-100Insulin Degludec	40	$30,435
Tresiba Flextouch U-200Insulin Degludec	16	$18,360
FarxigaDapagliflozin Propanediol	14	$18,330
Fiasp FlextouchInsulin Aspart (Niacinamide)	18	$17,497
NovologInsulin Aspart	56	$15,615
Novolog FlexpenInsulin Aspart	43	$14,479
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	75	$12,077

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Baltimore

Philip LevinBaltimore$489K
Adrian DobsBaltimore$149K
Todd BrownBaltimore$143K
Roberto SalvatoriBaltimore$53K
Nowreen HaqBaltimore$40K
Asif MohamedBaltimore$31K
Sherita GoldenBaltimore$27K
Jean ParkBaltimore$13K
Mansur ShomaliBaltimore$11K
Malek CheikhBaltimore$9K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →